-

09:33:23 PM

PTCT Stock News

PTCT - PTC Therapeutics Inc

06/20/22 4:00 PM

Nasdaq : PTCT

conferences

PTC Therapeutics to Host Call to Review Topline Results from Study 041 for Translarna™ (ataluren) in Nonsense Mutation Duchenne Muscular Dystrophy

PTC Therapeutics, Inc. (NASDAQ: PTCT) will host a conference call Tuesday, June 21 st at 8:00 a.m. E.T. to review topline results from Study 041 of Translarna™ (ataluren) in patients with nonsense mutation Duchenne muscular dystrophy. The call

RHEA-AI

neutral

06/09/22 8:00 AM

Nasdaq : PTCT

management

Biotech Investment Veteran Alethia Young Joins PTC Therapeutics' Board of Directors

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the election of Alethia Young to the company's Board of Directors. Ms. Young has more than 20 years of experience in healthcare and biotech equity research and investing. She is currently the

RHEA-AI

neutral

06/06/22 8:00 AM

Nasdaq : PTCT

conferences

PTC Therapeutics to Participate at William Blair 42nd Annual Growth Stock Conference

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the William Blair 42 nd Annual Growth Stock Conference on Thursday, June 9 at 2:20 p.m. ETThe presentation will be webcast live on the

RHEA-AI

neutral

06/03/22 8:00 AM

Nasdaq : PTCT

Preliminary Results Presented at ASCO Demonstrated Promising Clinical Efficacy with Unesbulin in Leiomyosarcoma Study

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced encouraging preliminary safety and efficacy results from its Phase 1B

RHEA-AI

neutral

05/31/22 1:00 AM

Nasdaq : PTCT

fda approval

FDA Approves Label Extension for Evrysdi® for Infants with Spinal Muscular Atrophy Under 2 Months Old

PTC Therapeutics, Inc. (NASDAQ: PTCT)

RHEA-AI

neutral

05/20/22 8:08 AM

Nasdaq : PTCT

PTC Therapeutics Receives Positive CHMP Opinion for Upstaza™ for the Treatment of AADC Deficiency

– First ever gene therapy directly administered into the brain –– Recommended for regulatory approval by EMA –– Results demonstrated sustained improvements in motor and cognitive function –– Conference call scheduled for Monday, May 23, at 8 a.m. ET –SOUTH PLAINFIELD, N.J. , May 20, 2022

RHEA-AI

positive

05/03/22 4:01 PM

Nasdaq : PTCT

earnings

PTC Therapeutics Provides a Corporate Update and Reports First Quarter Financial Results

RHEA-AI

neutral

04/29/22 4:30 PM

Nasdaq : PTCT

conferences

PTC Therapeutics to Participate at Upcoming Investor Conferences

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the following conferences:Bank of America Securities 2002 Healthcare Conference Tuesday, May 10 at 5:20 p.m. PT2022 RBC Capital Markets

RHEA-AI

neutral

04/19/22 8:00 AM

Nasdaq : PTCT

conferencesearnings

PTC Therapeutics to Host Conference Call to Discuss First Quarter 2022 Financial Results

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its first quarter 2022 financial results and provide an update on the company's business and outlook on Tuesday, May 3, at

RHEA-AI

neutral

04/14/22 8:30 AM

Nasdaq : PTCT

PTC Therapeutics Provides Update on EMA Regulatory Review Timeline For Its AADC Deficiency Gene Therapy Program

PTC Therapeutics, Inc. (NASDAQ:PTCT) announced today that it has completed the Scientific Advisory Group and Oral Explanation meetings for its gene therapy treatment for AADC deficiency (PTC-AADC) with

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 10 Next

PTCT Data

Websitewww.ptcbio.com
CeoStuart Peltz
Security namePTC Therapeutics Inc
Issue typecs
Sic code2834
Employees963
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address100 Corporate Ct
StateNew Jersey
CitySouth Plainfield
Zip07080-2400
CountryUS
Phone19082227000

About PTC Therapeutics Inc

PTC is a science-driven, global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. PTC's ability to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines and its mission to provide access to best-in-class treatments for patients who have an unmet medical need. The Company's strategy is to leverage its strong scientific expertise and global commercial infrastructure to maximize value for its patients and other stakeholders.